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(15.3%), psychotic disorders (4%) and drug use (2%). There were
no patients with eating or conduct disorders or IPI.
Conclusions Psychiatric morbidity is frequent in resistant-
epilepsy. Despite 38% of patients suffered from at least one axis I
diagnoses, IDD was the most prevalent condition and not included
in SCID interview.
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Introduction Cannabinoid hyperemesis syndrome (CHS), is cha-
racterized by recurrent episodes of severe nausea and intractable
vomiting, preceded by chronic use of cannabis. A pathogno-
monic characteristic is compulsive bathing in hot water. The
resolution of the problem occurs when cannabis use is stopped.
However, patients are often reluctant to discontinue cannabis.
Treatment with anti-emetic medication is ineffective. Case series
suggested haloperidol as a potential treatment. Other antipsy-
chotics as olanzapine has been used as anti-emetic treatment in
chemotherapy.
Objectives To describe three cases of patients with CHS whom
showed a successful response to olanzapine, even when, haloperi-
dol had failed.
Aims To present an alternative treatment for CHS which can offer
benefits over haloperidol.
Methods We present three cases of patients who suffered from
CHS and were admitted to emergency department. All patients
were treated with olanzapine after conventional anti-hemetic
treatment failure. One patient was also unsuccessfully treated with
haloperidol.
Results All three patients showed a good response to olanza-
pine treatment. Different presentations were effective: velotab
and intramuscular. Their nausea, vomits and agitation were ame-
liorated. They could be discharge after maintained remission of
symptoms.
Conclusions Olanzapine should be considered as an adequate
treatment for CHS. Its suitable receptorial profile, its availability in
different routes of administration and its side effects profile could
offer some benefits over haloperidol.
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Introduction Growing evidence has been collected over the com-
plex, intertwined pathophysiological connection among subclinical
cardiovascular (CV) disease, i.e. atherosclerosis, systemic low pro-
inflammatory states and psychiatric disorders/symptomatology
(anxiety, depression), with controversial results.
Aim Aim of this study was to investigate the possible link
between subclinical CV risk factors (atherosclerosis), depressive
symptoms, and inflammation.
Methods Cross-sectional study. Inclusion criteria: outpatients
aged ≥40 years, attending colonoscopy after positive faecal occult
blood test, negative medical history for cancer. Collected data:
blood pressure, glycaemia, lipid profile, waist circumference,
BMI, PCR (C reactive protein), LPS (bacterial lipopolysaccharide),
ultrasound carotid intima-media thickness (c-IMT). Psychometric
tests: HADS, TCI, IMSA, SF36. Statistical analysis performed with
STATA13.
Results The 54 patients enrolled were equally distributed by gen-
der. CV risk factors were common in the study population, with 33
patients (61.11%) with hypertension, 14 (25.93%) with hypergly-
caemia, 20 (37.4%) with hypertriglyceridemia, 19 (35.19%) with low
HDL and 64.81% with overweight. High levels of PCR were found in
24 subjects (44.44%). Right c-IMT was increased in 26.41% of the
sample, and 11.32% had an atheromatous plaque. Left c-IMT was
increased in 24.53% of patients, with a plaque in 7.55% of them. Cli-
nically relevant depressive symptoms were found in the 18.87% of
the sample and were statistically significantly associated with PCR
(OR = 28.63; P = 0.01).
Conclusions Evidence contributing to the so-called “inflamma-
tion theory” of depression and supporting the association between
mood and CV disorders was here collected, supporting the need
for a multidisciplinary approach to the diagnosis and treatment
of such conditions, assuming a clinically-translated PNEI (psycho-
neuro-endocrino-immunological) perspective.
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